What is the growth forecast for the Devic’s Syndrome Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing prevalence.

What are the key drivers of the Devic’s Syndrome Treatment market?

Key drivers include rising awareness, advancements in treatment options, and growing investment in research.

What are the major challenges facing the Devic’s Syndrome Treatment market?

Challenges include high treatment costs, limited availability of treatments, and lack of awareness.

Which regions are leading the Devic’s Syndrome Treatment market?

North America and Europe are leading the market due to high prevalence and advancements in healthcare.

Who are the top companies in the Devic’s Syndrome Treatment market?

Top companies include pharmaceutical giants and biotech firms investing in research and development.

What future opportunities exist in the Devic’s Syndrome Treatment market?

Future opportunities include development of new treatments, increasing awareness, and expanding into emerging markets.

How is technology impacting the Devic’s Syndrome Treatment market?

Technology is improving diagnosis, treatment options, and patient outcomes, driving growth in the market.

What is the regulatory landscape like for the Devic’s Syndrome Treatment market?

The regulatory landscape is complex, with stringent regulations and ongoing efforts to improve treatment approval processes.

What is the future outlook for the Devic’s Syndrome Treatment market?

The future outlook is positive, with expected growth driven by increasing prevalence and advancements in treatment options.

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report 2026: Analyst-Verified Data & Forecast

Devic’s Syndrome (Neuromyelitis Optica) Treatment by Application (Hospitals, Clinic, Others), by Types (Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size | CAGR 8.2 Forecast 2033

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Overview

The Devic’s Syndrome (Neuromyelitis Optica) Treatment market refers to the industry focused on developing and providing treatments for Neuromyelitis Optica, a rare autoimmune disorder. As the Devic’s Syndrome (Neuromyelitis Optica) Treatment market size is expected to reach $2.5 billion by 2026, the growth outlook and market forecast indicate a significant expansion of the industry, driven by increasing awareness and advancements in treatment options. The market forecast suggests a compound annual growth rate (CAGR) of 8.5% during the forecast period, with key drivers including technological advancements, regulatory support, and changing consumer behavior.

Loading chart…

The largest region in the Devic’s Syndrome (Neuromyelitis Optica) Treatment market is North America, while the fastest-growing region is Asia-Pacific. Key forces shaping the industry include technology shifts towards more targeted and effective treatments, regulatory support for rare disease research, and changing consumer behavior driven by increasing awareness and patient advocacy. As the industry continues to evolve, strategic planners and business development teams must stay informed about the latest developments and trends to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alexion Pharmaceuticals, Inc.; Teva Pharmaceuticals; Fresenius Kabi AG; Pharmacia & Upjohn (a subsidiary of Pfizer); Lupin Ltd.; Sagent Pharmaceuticals, Inc.; Zydus Pharmaceuticals, Inc.; Sandoz Inc. (Novartis); Alkem Laboratories Ltd.; Mylan Pharmaceuticals, Inc.; Hoffmann-La Roche/ Chugai Pharmaceutical; MedImmune LLC; RemeGen, Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Devic’s Syndrome (Neuromyelitis Optica) Treatment market is poised for significant growth, driven by increasing awareness and advancements in treatment options. The growth forecast for the Devic’s Syndrome (Neuromyelitis Optica) Treatment market size is expected to be substantial, driven by the rising prevalence of the disease and the expanding patient population.

Growth Drivers2 items

The development of novel therapies, such as monoclonal antibodies and small molecule inhibitors, is expected to drive growth in the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, offering improved treatment outcomes and enhanced patient care.

Increasing investments in research and development, coupled with government initiatives to support rare disease treatment, are anticipated to fuel the growth forecast for the Devic’s Syndrome (Neuromyelitis Optica) Treatment market size.

Restraints2 items

The high cost of treatment and limited access to healthcare facilities in developing regions are expected to hinder the growth of the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, particularly in low-income countries.

The lack of standardization in treatment protocols and the need for personalized medicine approaches may also restrain the growth of the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, as healthcare providers and patients seek more tailored treatment options.

Opportunities2 items

The emergence of biomarkers and personalized medicine approaches is expected to create new opportunities for growth in the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, enabling targeted and more effective treatment strategies.

The increasing focus on rare disease treatment and the growing awareness of Devic’s Syndrome (Neuromyelitis Optica) among healthcare professionals and patients are anticipated to drive growth in the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, particularly in developed regions.

Challenges2 items

The complex nature of Devic’s Syndrome (Neuromyelitis Optica) and the lack of understanding of its underlying mechanisms pose significant challenges for the development of effective treatments, hindering the growth forecast for the Devic’s Syndrome (Neuromyelitis Optica) Treatment market size.

The need for long-term treatment and the associated costs, as well as the potential for treatment side effects, are expected to challenge the growth of the Devic’s Syndrome (Neuromyelitis Optica) Treatment market, particularly in regions with limited healthcare resources.

Market Segmentation

Loading chart…

The Devic’s Syndrome (Neuromyelitis Optica) Treatment market can be segmented based on Application, which refers to the specific use of treatments for Devic’s Syndrome. This segmentation category contributes to the overall market size by identifying the areas where treatments are most needed and where research should be focused. The application segment includes various subtypes, such as acute treatment and disease-modifying therapies. Understanding the application segment is crucial for Devic’s Syndrome (Neuromyelitis Optica) Treatment segmentation as it allows for a more targeted approach to treatment development and marketing.

Another key segmentation category in the Devic’s Syndrome (Neuromyelitis Optica) Treatment market is Types, which encompasses the different forms of treatments available. This includes subtypes such as immunosuppressive medications and plasma exchange therapy. The types segment contributes to the overall market size by providing a breakdown of the various treatment options available and their respective market shares. Analyzing the types segment is essential for understanding the market taxonomy of Devic’s Syndrome treatments and identifying areas for growth and development.

Devic’s Syndrome (Neuromyelitis Optica) Treatment Segmentation Breakdown10 items

Application

Hospitals

Clinic

Others

Types

Eculizumab

Methylprednisolone

Azathioprine

Mycophenolate Mofetil

Rituximab

Regional Insights

Loading chart…

The Devic's Syndrome (Neuromyelitis Optica) Treatment market is poised for significant growth, driven by increasing adoption and investments in key regions. North America is the largest region, accounting for approximately 40% of the market share, driven by factors such as advanced infrastructure, high ecosystem maturity, and favorable policies. Key drivers in this region include rising awareness about Devic's Syndrome, growing demand for effective treatments, and ongoing research initiatives.

The fastest-growing region is Asia Pacific, with a growth rate driven by increasing demographics, improving healthcare infrastructure, and expanding investment in the region. Europe accounts for around 25% of the market share, driven by factors such as government support, research collaborations, and a mature pharmaceutical industry. Latin America and Middle East & Africa are also expected to contribute to the Devic's Syndrome (Neuromyelitis Optica) Treatment market growth, with key drivers including growing patient populations, increasing access to healthcare, and rising investment in these regions.

Regional Drivers4 items

North America: rising awareness, growing demand, ongoing research

Europe: government support, research collaborations, mature pharmaceutical industry

Asia Pacific: increasing demographics, improving healthcare infrastructure, expanding investment

Latin America and Middle East & Africa: growing patient populations, increasing access to healthcare, rising investment

Competitive Landscape

The Devic’s Syndrome (Neuromyelitis Optica) Treatment market exhibits a moderately consolidated structure, with a mix of global players and local companies competing for market share. The Devic’s Syndrome (Neuromyelitis Optica) Treatment competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional expansion and partnerships to stay competitive.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players focus on strategic initiatives to maintain their market position.

Alexion Pharmaceuticals, Inc. - regional expansion

Teva Pharmaceuticals - vertical integration

Fresenius Kabi AG - premium pricing

Pharmacia & Upjohn - innovation pipeline

Lupin Ltd. - local manufacturing

Sagent Pharmaceuticals, Inc. - OEM tie-ups

Key Devic’s Syndrome (Neuromyelitis Optica) Treatment Companies13 items

Alexion Pharmaceuticals, Inc.

Teva Pharmaceuticals

Fresenius Kabi AG

Pharmacia & Upjohn (a subsidiary of Pfizer)

Lupin Ltd.

Sagent Pharmaceuticals, Inc.

Zydus Pharmaceuticals, Inc.

Sandoz Inc. (Novartis)

Alkem Laboratories Ltd.

Mylan Pharmaceuticals, Inc.

Hoffmann-La Roche/ Chugai Pharmaceutical

MedImmune LLC

RemeGen, Ltd.

Market Ecosystem

The Devic’s Syndrome (Neuromyelitis Optica) Treatment ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream activities. This ecosystem involves the creation and capture of value through the development, manufacturing, and distribution of treatments, as well as the provision of related services. Technology providers and suppliers form the upstream segment, while integrators, channels, and end users constitute the midstream and downstream segments, respectively.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce treatment medications

Technology providers — develop innovative treatment platforms

Distributors / channel partners — deliver treatments to healthcare providers

Service providers / after-sales — offer patient support and monitoring services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — oversee treatment approvals and compliance

Within the Devic’s Syndrome (Neuromyelitis Optica) Treatment ecosystem, control points are primarily held by regulators and treatment manufacturers, as they influence adoption through approvals and product development. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards, including those set by regulatory bodies. Switching costs and partnerships between treatment manufacturers and distributors can also impact the ecosystem. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and healthcare systems, highlighting the need for a comprehensive value chain analysis to understand these complexities.

Recent Industry Insights

The Devic’s Syndrome (Neuromyelitis Optica) Treatment industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been key partnerships, such as the collaboration between pharmaceutical companies to develop novel therapies, and mergers & acquisitions that have expanded the reach of existing treatments. Furthermore, product launches, including new monoclonal antibodies, have improved treatment options for patients.

Regulatory changes have also played a crucial role, with approvals from authorities such as the FDA and EMA, allowing for the introduction of new treatments. Additionally, there has been a shift in consumer trends, with increased awareness and advocacy for Devic’s Syndrome, driving demand for more effective and targeted therapies. Funding rounds and expansions have also been prominent, with investments in research and development aimed at advancing the understanding and management of the disease.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Devic's Syndrome (Neuromyelitis Optica) Treatment market outlook. The market attractiveness is moderate, driven by the increasing prevalence of the disease and the availability of targeted therapies. The competitive intensity is high, with several key players vying for market share. The long-term outlook is positive, with the market expected to grow due to advancements in treatment options and rising awareness about the disease.

The innovation landscape is evolving, with a focus on personalized medicine and immunomodulatory therapies. The demand-supply balance is expected to be stable, with manufacturers working to meet the growing demand for effective treatments. However, key risk factors such as regulatory changes and pricing pressures may impact the market. Overall, the Devic's Syndrome (Neuromyelitis Optica) Treatment market presents opportunities for growth and innovation, driven by the need for effective treatments and the increasing understanding of the disease.

11 items

1. Executive Summary

2. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinic

6.1.3. Others

6.2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Eculizumab

6.2.2. Methylprednisolone

6.2.3. Azathioprine

6.2.4. Mycophenolate Mofetil

6.2.5. Rituximab

6.3. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Competition by Key Manufacturers

8.1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Devic’s Syndrome (Neuromyelitis Optica) Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alexion Pharmaceuticals, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Teva Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Fresenius Kabi AG

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pharmacia & Upjohn (a subsidiary of Pfizer)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Lupin Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sagent Pharmaceuticals, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Zydus Pharmaceuticals, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sandoz Inc. (Novartis)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Alkem Laboratories Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mylan Pharmaceuticals, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hoffmann-La Roche/ Chugai Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. MedImmune LLC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. RemeGen, Ltd.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market

Figure 4: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Drivers

Figure 5: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Challenges

Figure 6: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Trends

Figure 7: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Opportunity

Figure 8: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Restraint

Figure 9: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Value (USD Million) By Region

Figure 15: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Value (USD Million) By Region

Figure 23: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Value (USD Million) By Region

Table 10: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alexion Pharmaceuticals, Inc. Basic Information And Sales Area

Table 31: Alexion Pharmaceuticals, Inc.. Products Portfolio

Table 32: Teva Pharmaceuticals Basic Information And Sales Area

Table 33: Teva Pharmaceuticals. Products Portfolio

Table 34: Fresenius Kabi AG Basic Information And Sales Area

Table 35: Fresenius Kabi AG. Products Portfolio

Table 36: Pharmacia & Upjohn (a subsidiary of Pfizer) Basic Information And Sales Area

Table 37: Pharmacia & Upjohn (a subsidiary of Pfizer). Products Portfolio

Table 38: Lupin Ltd. Basic Information And Sales Area

Table 39: Lupin Ltd.. Products Portfolio

Table 40: Sagent Pharmaceuticals, Inc. Basic Information And Sales Area

Table 41: Sagent Pharmaceuticals, Inc.. Products Portfolio

Table 42: Zydus Pharmaceuticals, Inc. Basic Information And Sales Area

Table 43: Zydus Pharmaceuticals, Inc.. Products Portfolio

Table 44: Sandoz Inc. (Novartis) Basic Information And Sales Area

Table 45: Sandoz Inc. (Novartis). Products Portfolio

Table 46: Alkem Laboratories Ltd. Basic Information And Sales Area

Table 47: Alkem Laboratories Ltd.. Products Portfolio

Table 48: Mylan Pharmaceuticals, Inc. Basic Information And Sales Area

Table 49: Mylan Pharmaceuticals, Inc.. Products Portfolio

Table 50: Hoffmann-La Roche/ Chugai Pharmaceutical Basic Information And Sales Area

Table 51: Hoffmann-La Roche/ Chugai Pharmaceutical. Products Portfolio

Table 52: MedImmune LLC Basic Information And Sales Area

Table 53: MedImmune LLC. Products Portfolio

Table 54: RemeGen, Ltd. Basic Information And Sales Area

Table 55: RemeGen, Ltd.. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Value (USD Million) By Region

Table 61: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alexion Pharmaceuticals, Inc.; Teva Pharmaceuticals; Fresenius Kabi AG; Pharmacia & Upjohn (a subsidiary of Pfizer); Lupin Ltd.; Sagent Pharmaceuticals, Inc.; Zydus Pharmaceuticals, Inc.; Sandoz Inc. (Novartis); Alkem Laboratories Ltd.; Mylan Pharmaceuticals, Inc.; Hoffmann-La Roche/ Chugai Pharmaceutical; MedImmune LLC; RemeGen, Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options